hVIVO (LON:HVO) Shares Down 44.1% - Time to Sell?

Shares of hVIVO plc (LON:HVO - Get Free Report) were down 44.1% during mid-day trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 9.06 ($0.12). Approximately 82,360,656 shares changed hands during mid-day trading, an increase of 2,310% from the average daily volume of 3,417,799 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Upgrades and Downgrades

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research report on Friday.

hVIVO Trading Down 46.3%

The business's 50-day moving average price is GBX 16.16 and its 200 day moving average price is GBX 18.13. The company has a market cap of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61.

hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,459.93). 14.03% of the stock is currently owned by insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.